Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1885 results
January 2018
-
Featured News
Novartis recognized as a global leader in sustainable water and climate management
Novartis is one of 73 companies included in the 2017 Water A List by CDP, the nonprofit global environmental disclosure platform.
-
Ad hoc release
Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
Lutathera marks first FDA Approval for a Peptide Receptor Radionuclide Therapy (PRRT) Advanced Accelerator Applications is a newly established subsidiary of Novartis Lutathera… -
Press release
Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss
Novartis enters into a licensing and supply agreement to develop, register and commercialize investigational gene therapy voretigene neparvovec outside the US; Spark Therapeutics retains US rights… -
Press release
Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase
Full year sales grew 2% (cc, +1% USD) as strong performance of our growth drivers, including Cosentyx and Entresto, more than offset Gleevec/Glivec generic erosion: Cosentyx grew to USD 2.1… -
Press release
Novartis a enregistré, en 2017, une belle performance opérationnelle et des innovations majeures, entrant ainsi dans une nouvelle phase de croissance
Hausse de 2% (tcc, +1% USD) des ventes sur l'exercice complet, car l'excellente performance de nos moteurs de croissance, notamment Cosentyx et Entresto, a plus que compensé l'érosion due aux… -
Press release
Novartis erzielt 2017 eine gute operative Performance sowie wegweisende Innovationen und ist gut gerüstet für die nächste Wachstumsphase
Der Umsatz steigt im Geschäftsjahr um 2% (kWk, +1% USD), wobei die starke Performance unserer Wachstumstreiber, wie Cosentyx und Entresto, die Einbussen durch Generika bei Glivec/Gleevec mehr als… -
Press release
Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients who have failed multiple prior preventive treatments
LIBERTY is the first migraine prevention trial of its kind conducted specifically in patients who have tried multiple therapies without success, and are in need of additional treatment options… -
Press release
AveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CHICAGO, Jan. 22, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced the closing of its previously announced underwritten public offering of 4,509,840 shares of its common stock… -
Press release
Novartis completes tender offer for Advanced Accelerator Applications S.A. and announces commencement of subsequent offering period
Transaction expands Novartis Oncology neuroendocrine tumor (NET) treatment portfolio and adds radiopharmaceutical technology platform Lutathera® (lutetium Lu 177 dotatate), with a US PDUFA date… -
Press release
Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars
Collaboration aims to help patients worldwide gain access to a range of high-quality, affordable immunology and oncology biologics Partnership will be an important part of Sandoz and Biocon… -
Press release
Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
Filing acceptance marks second Priority Review granted to Kymriah by the FDA for two distinct indications, underscoring the potential of first ever FDA-approved CAR-T therapy EMA granted… -
Press release
AveXis Announces Pricing of Public Offering of Common Stock
CHICAGO, Jan. 16, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced the pricing of an underwritten public offering of 3,921,600 shares of its common stock at a public offering…